Naar homepage     
Chronische Cerebro-Spinale Veneuze Insufficiëntie
Aanmelden op het CCSVI.nl forum
Lees Voor (ReadSpeaker)    A-   A+
Over CCSVI.nl | Zoeken | Contact | Forum
CCSVI.nl is onderdeel van de
Franz Schelling Website
meer informatie
  
Wednesday, December 22, 2010 7:18 PM | Ken Torbert Volg link

Dear Mark,



I was recently forwarded a copy of an email which you had sent to one of
your patients regarding the CCSVI issue. I was not surprised by your

unwavering belief that CCSVI is nonsense but was slightly taken aback by

your over-the-top view that all those who think that CCSVI treatment

may be of value are nothing more than frenzied, cult members.  I was

also somewhat surprised that you mentioned me but was glad you asked an

important question ”who am I to question the word of the

many self-acclaimed experts who feed this frenzy like the rock doctor

Embry whose lifelong study of lifeless objects has given him the wisdom

to comment on such complex issues?”


 


You are correct that my primary scientific research activity for the past
42 years has revolved around inanimate rocks, mainly those in the

Canadian Arctic Archipelago. I’ll be glad to send you some of my

published geological papers if you have an interest in such things.



I must point out that it has not been my geological studies which have
“given me the wisdom” to comment on complex issues associated with

multiple sclerosis. My knowledge on MS comes from reading thousands of

scientific papers and countless abstracts on MS and related subjects

(e.g. nutrition, autoimmunity in general, and more recently vascular

issues).  My pursuit of scientific knowledge in regards to MS has been

driven by a desire to ensure my son is doing everything he can to

prevent the progression of his MS.  



I would emphasize that I try hard to make sure any written comments I make on MS,
especially recommendations on how to help control disease progression,

are backed by solid science, including both empirical data and critical,

rational reasoning.  I suppose you could say that many years of

geological research have instilled this hard-core, scientific approach

so perhaps you are not entirely wrong with your statement that the

source of my MS “wisdom” is my geological research.



I thought it might be useful if I discussed how we sharply differ on three
important scientific issues which dominate decisions regarding the

treatment of MS. These issues are CCSVI, vitamin D and the CRAB drugs.

These differences show how we significantly vary when it comes to doing

science and to using science to guide actions. Following this, I will

wrap-up with a few possibilities on why such differences between us

exist, despite the fact we both would claim we are scientists wanting to

understand MS so as to allow us to make recommendations on how to treat

it.




CCSVI


The first topic is CCSVI which continues to divide the MS community. As a scientist, I
try to stay up to date on the literature but it wasn’t until July, 2009

that I came upon Dr Zamboni’s work, 4 months after he had published his

watershed paper on CCSVI. After reading that paper, I immediately read

all the available papers on CCSVI as well as major past references on

vascular issues in MS. Once I had completed my literature research,

which included carefully going through the Zamboni papers up to three

times each, it was apparent that either impaired venous drainage was

very likely an important factor in MS or that Dr Zamboni and his

associates were incompetent or frauds. There basically was no middle

ground given the apparent robustness of the Zamboni research.



A review of the extensive scientific contributions of Dr Zamboni and his
colleagues over the past 25 years removed any doubt as to their

impeccable scientific credentials and their solid competency when it

comes to vascular research. Thus, their impressive clinical and

theoretical studies on CCSVI, combined with past studies on vascular

issues associated with MS, and the fact that CCSVI nicely explained some

previously inexplicable features of MS (e.g.  venocentricity of

lesions, associated iron deposits, continued disease progression despite

the complete destruction of the immune system),  gave me no choice but

to accept the proposition that it was very likely that CCSVI was an

important factor in MS. This in turn led me to facilitate and encourage

the dissemination of CCSVI information and to call for extensive

research into CCSVI and MS in August 2009.



Since my initial immersion into the CCSVI literature, I have closely followed
CCSVI research and this has included visiting with some of the

researchers themselves. I have been most impressed with the CCSVI

research being done at the University of Buffalo and their work,

involving 500 subjects, has robustly confirmed the high association of

CCSVI with MS. Such a high association, the plausible biological

mechanisms which link CCSVI to the MS disease process, and the

established nature of the venous problems associated with CCSVI,

establish beyond a reasonable scientific doubt that CCSVI plays a role

in the MS disease process.



I have also kept a close watch on the results of worldwide CCSVI treatments because such results, due
to their high numbers, are important scientific data that cannot be

ignored. Currently, there are at least 75 centres worldwide doing CCSVI

treatment and between 100 and 200 procedures are now being done each

day. These treatments involve the use of venography which is the gold

standard for the identification of CCSVI and, of the 12,000+ patients

treated so far, over 90% have had undoubted CCSVI. Furthermore, there

have been thousands of well documented cases of substantial improvement

of a variety of MS symptoms following CCSVI treatment.



As a scientist, I cannot ignore the CCSVI treatment data and to do so would
be bordering on scientific incompetence/fraud. To sum up, the published

scientific data on CCSVI and the many thousands of clinical procedures

which have identified and treated CCSVI leave no reasonable doubt as to

the existence of CCSVI and that it plays a role in the MS disease

process.



I would contrast my objective, scientific appraisal of CCSVI with your emotional and non-scientific approach. I
assume the first time you were exposed to the science of CCSVI was

through the CTV documentary and that you had failed to read the papers

which had been published on this topic before that time. Your public

response to a group of MS patients that the Zamboni work was a hoax

before you had read his papers, reveals a complete lack of scientific

method and objectivity by you on this subject. Furthermore, your

insistence on ignoring the results of many thousands of CCSVI procedures

also underscores your inability to take an unbiased, scientific

approach when it comes to CCSVI. I will discuss possible reasons for

such a failure later.



The bottom line is that you have not spent time with the CCSVI researchers, you have not read most of the
200+ scientific papers which bear directly on the CCSVI question, and

you have not taken the time to evaluate the results of the huge number

of CCSVI procedures which have been done. Any claim that your comments

regarding CCSVI are science-based is not supportable.  Thus, when it

comes to CCSVI my comments on the subject are given much more weight

than yours simply because I know far more about the subject than you do

and most importantly, I have taken an objective, scientific approach to

CCSVI and MS, not an emotional, highly prejudiced one like you have. I

can only encourage you to try to be more objective and scientific when

it comes to CCSVI.



Vitamin D


The next topic is the role of vitamin D in MS. When I began my studies of
the MS literature, my main goal was to identify environmental factors

involved in MS. It seemed this would be the best approach for devising

potential therapies for treating the disease. By 1999 there was enough

solid and diverse scientific data to indicate that vitamin D deficiency

was involved in MS. Given this, I advocated for the use of vitamin D

supplements both as a strategy to prevent MS in the first place and to

treat it. This was a classic case of a scientifically-backed therapy

which offered nothing to lose (vitamin D is extremely low cost and

completely safe) and all to gain in terms of prevention and treatment.

At this time I also published a short note in Annals of Neurology on

vitamin D and lesion formation (with a recommendation for a 4000 IU

supplement) and I made available on the internet a comprehensive

document on the science of vitamin D and MS.



Notably over the past 10 years there have been scores of studies on vitamin D and MS,
all of which have supported and confirmed what we knew back in 1999 –

there is a good chance adequate vitamin D will prevent MS in many cases

and that it will have therapeutic value for those with MS. I would say

that I have read at least 750 papers on vitamin D with at least 250 of

those directly related to vitamin D and MS. Given that my scientific

abilities and literature research allowed me to identify vitamin D as a

useful therapy for MS in 1999, the question becomes what did your

scientific approach achieve for you regarding vitamin D and MS.



You may recall in November,2006 we both attended an AAN  MS Guideline
meeting in Boston. I gave a presentation on vitamin D and MS and the

potential value of developing a guideline on such a topic. Following my

talk, you made light of the concept of vitamin D for MS calling it

alternative medicine that had no place in the meeting. It was very

obvious you had not read any of the vitamin D literature or you would

not have made such an unsupportable and revealing statement.



I have also learned that you do not recommend adequate vitamin D (enough
to raise one’s 25D level to between 125-175 nmol/l) to your MS patients

and you do not let your patients know that there is a reasonable chance

that adequate vitamin D from birth onwards will prevent MS. It is clear

that you have not taken a scientific approach when it comes to vitamin D

and MS and your patient care has consequently suffered. Again, I can

only suggest you take some time to review all the vitamin D and MS

literature in an objective and comprehensive fashion.



CRAB drugs    


The CRAB  drugs (Copaxone, Rebif, Avonex, Betaseron) is one topic I am sure
you know lots about given your involvement in clinical trials and your

very strong and lucrative financial ties to the drug companies that

manufacture these drugs. I also have a great interest in these drugs

because they represent a potential therapy for my son.



When it comes to such drugs, the key question is whether or not they affect
the progression of the disease or not. If they do, then they would be a

reasonable therapeutic option despite their high cost and adverse side

effects. However, if they do not slow progression, then I would say they

are possibly worse than useless. So the obvious scientific question,

which we both are interested in, is whether or not any of the CRAB drugs

slow MS progression.



Given that you prescribe such drugs to your newly diagnosed patients and give talks (often for money)
advocating the use of such drugs, I can only presume that you firmly

believe that the drugs do slow disease progression. I am not sure what

you base such a belief on but I have to assume it is mainly based on the

clinical trials which tested the effect of the drugs using frequency of

MS relapse and number of new MS lesions as proxies for determining if a

given drug affected progression or not. You and I both know that there

have been no clinical trials which have lasted long enough to directly

determine if any of the CRAB drugs actually do slow MS progression or

not.



From a scientific perspective, it became essential to determine if frequency of MS relapse and new lesion formation
correlated to MS disease progression and were thus valid proxies in

clinical trials. I have read most studies connected with the MS drugs

and over the last few years have been impressed with the studies which

have shown that those two proxies do NOT correlate with disease

progression. In fact it was found those with fewer attacks progressed

faster and farther! 



To emphasize this critical point I have to quote Dr George Ebers, one of the premier MS researchers in the
world on this. Dr Ebers states “Clinical trials of multiple sclerosis

have been uniform in utilising invalidated outcome measures. This has

occurred to a degree to which it is difficult to find parallels in

medicine in general. It is quite clear from natural history studies that

relapses have very little if anything to do with long term outcome. Similarly, MRI

measures have been thoroughly evaluated within large datasets and found

to be similarly non-predictive for meaningful outcomes.” These are conclusions from hard science and have to be respected and used when it comes to actions regarding the CRAB drugs.



I assume you have read the key papers which demonstrate that relapse rate
and MS lesion formation cannot be used to determine if a given drug is

of value for slowing MS. I trust you will agree that currently we have

no good scientific evidence that the CRAB drugs slow MS progression. In

fact, we now have a three long term studies which indicate that the drugs do not slow MS progression

by showing that those on the drugs reached the same EDSS end points in

the same time as those not on the drugs (Boggild et al, 2009; Veugelers

et al, 2009; Ebers et al, 2010).



Given the above scientific evidence and reasoning, I have advised my son not to use a
CRAB drug and I also advise others not to use a CRAB drug which provides

no benefit and which has adverse side effects such as flu-like symptoms

and painful injection site reactions. It is somewhat bothersome that you

claim to be a scientist and to follow the dictates of evidence-based

medicine but continue to prescribe drugs for which we have no reliable

scientific evidence that they do any good. In fact, the current data

indicate they do not work.


 


I have to again quote George Ebers on the problem of “widespread embracing of dubious and poorly validated outcomes by some MS
investigators, often in contexts where there are egregious conflicts of

interest, threaten academic credibility not to mention long term

professional autonomy.” There is no doubt that many

neurologists are prescribing the CRAB drugs, not because the science

says they work, but because it is financially advantageous to do so.

Given your “egregious conflicts of interest” when it

comes to the CRAB drugs and your disregard for the science concerning

these drug, I assume you can understand why you have no credibility on

this subject.



Summary


I have pointed out three main differences between us when it comes to various
factors and MS. I objectively follow the available science which tells

us that:


1)    CCSVI is highly associated with MS and is very likely an important part of the disease process,


2)    Vitamin D deficiency is an important factor in the onset and progression of MS.


3)    The CRAB drugs do not have any effect on MS disease progression.



These science-based conclusions have led me to the following science-based recommendations that anyone with MS:


1)    Be tested and, if need be, treated for CCSVI.


2)    Take an adequate vitamin D supplement and ensure any first degree relative also takes such a supplement.


3)    Do not use any of the CRAB drugs.



On the other hand you ignore much of the current science and, on the basis
of blind faith rather than scientific analysis, tell your patients

that:


1)    CCSVI does not exist and persons with MS who see potential value in CCSVI treatment are frenzied cult members.


2)    Vitamin D supplementation represents alternative medicine and has no place in MS treatment or prevention.


3)    The CRAB drugs are of value and should be used by persons with RRMS.



Finally we are left with the question of why I have chosen an unbiased
scientific path whereas you have gone in the opposite direction. My only

hypothesis to explain this is that your financial ties to the drug

companies have prejudiced you against any non-drug therapy such as

adequate vitamin D and CCSVI treatment and made you blind to the robust

data which demonstrate the drugs do not slow MS progression. On the

other hand, with my son having MS, I have all to lose and nothing to

gain by not ensuring that I carefully examine all scientific hypotheses

for MS in a rigorous and unbiased manner. Perhaps also the fact I was

trained as a scientist (PhD) whereas you were trained as an MD (ie

engineer) might also come into play when it comes to the great

difference in our application of science for helping persons with MS.



I hope this answers your question of why persons with MS trust what I
have to say about various proposed therapies for MS far more than they

trust you. They can tell the difference between an objective,

science-based analysis and a self-serving, unscientific opinion every

time.   



Ashton Embry